ReviewJournal of clinical and translational hepatology2022
Neoadjuvant and Adjuvant Therapy in Intrahepatic Cholangiocarcinoma.
Review in Journal of clinical and translational hepatology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 2 syntheses or guidelines pooled it, 26 citations in OpenAlex.
- Perineural invasion in intrahepatic cholangiocarcinoma: Meta-analysis of prevalence, association with tumor features, and impact on survival.JHEP reports : innovation in hepatology · 2026Pooled it
- Neoadjuvant chemotherapy followed by surgery versus upfront surgery for intrahepatic cholangiocarcinoma: a systematic review and meta-analysis.BMC cancer · 2025Pooled it
- Cholangiocarcinoma in the Era of Precision Medicine: Emerging Insights and Therapeutic Strategies.Current pharmaceutical design · 2026Review
- Evolving role of radiation therapy in advanced/metastatic intrahepatic cholangiocarcinoma.World journal of gastrointestinal pharmacology and therapeutics · 2025Review
- The future of hepatobiliary surgical oncology.Hepatobiliary surgery and nutrition · 2025Article
- Mass-forming intrahepatic cholangiocarcinoma: treatment outcomes after curative-intent resection in an Australian tertiary referral hospital.ANZ journal of surgery · 2025Article
- Who benefits from adjuvant chemotherapy? Identification of early recurrence in intrahepatic cholangiocarcinoma patients after curative-intent resection using machine learning algorithms.Frontiers in oncology · 2025Article
- A preliminary study of developing an MRI-based model for postoperative recurrence prediction and treatment direction of intrahepatic cholangiocarcinoma.La Radiologia medica · 2024Article
- ASO Author Reflections: Radical Resection After Neoadjuvant Therapy for Intrahepatic Cholangiocarcinoma-Emerging Technologies in Comprehensive Treatment Strategies.Annals of surgical oncology · 2024Article
- [A case of giant hilar cholangiocarcinoma accompanied by hyperbilirubinemia achieved disease stabilization via hepatic artery infusion chemotherapy combined with targeted therapy].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2024Article
- Machine learning to predict the early recurrence of intrahepatic cholangiocarcinoma: A systematic review and meta‑analysis.Oncology letters · 2024Article
- Impact of Lymph Node Dissection for Patients With Clinically Node-Negative Intrahepatic Cholangiocarcinoma: A Multicenter Cohort Study.World journal of oncology · 2024Article
- Update on the Diagnosis and Treatment of Combined Hepatocellular Cholangiocarcinoma.Journal of clinical and translational hepatology · 2024Review
- Research progress and prospect of postoperative adjuvant therapy for resectable intrahepatic cholangiocarcinoma.Frontiers in pharmacology · 2024Review
- Predictive Model of Oxaliplatin-induced Liver Injury Based on Artificial Neural Network and Logistic Regression.Journal of clinical and translational hepatology · 2023Article
- Impact of Staging Concordance and Downstaging After Neoadjuvant Therapy on Survival Following Resection of Intrahepatic Cholangiocarcinoma: A Bayesian Analysis.Annals of surgical oncology · 2023Article
- Development and external validation of a prognosis model to predict outcomes after curative resection of early-stage intrahepatic cholangiocarcinoma.Frontiers in surgery · 2023Article
- Newest Therapies for Cholangiocarcinoma: An Updated Overview of Approved Treatments with Transplant Oncology Vision.Cancers · 2022Review
- Identification of macrophage correlated biomarkers to predict the prognosis in patients with intrahepatic cholangiocarcinoma.Frontiers in oncology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Intrahepatic cholangiocarcinoma (ICC) is the second most common primary liver cancer and causes major economic and health burdens throughout the world. Although the incidence of ICC is relatively low, an upward trend has been seen over the past few decades. Owing to the lack of specific manifestations and tools for early diagnosis, most ICC patients have relatively advanced disease at diagnosis. Thus, neoadjuvant therapy is necessary to evaluate tumor biology and downstage these patients so that appropriate candidates can be selected for radical liver resection. However, even after radical resection, the recurrence rate is relatively high and is a main cause leading to death after surgery, which makes adjuvant therapy necessary. Because of its low incidence, studies in both neoadjuvant and adjuvant settings of ICC are lagging compared with other types of malignancy. While standard neoadjuvant and adjuvant regimens are not available in the current guidelines due to a lack of high-level evidence, some progress has been achieved in recent years. In this review, the available literature on advances in neoadjuvant and adjuvant strategies in ICC are evaluated, and possible challenges and opportunities for clinical and translational investigations in the near future are discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.